Clay Siegall, Ph.D.

President and Chief Executive Officer

Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company’s acquisition of Cascadian Therapeutics. Pfizer, Inc. agreed to purchase Seagen for $43 billion in March 2023. Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and previously at the National Cancer Institute. He earned a PhD in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.